Tag

Reshma Kewalramani

1 article

Vertex to Acquire Crinetics for $10B

Vertex Pharma announced cash acquisition of Crinetics at $85 per share, valuing equity at about $10 billion ($8.8 billion net). Crinetics shares jumped over 100% while Vertex stock slipped 0.5% after